Insmed, Inc. (NASDAQ:INSM) has been given a consensus rating of “Hold” by the eight ratings firms that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $22.75.
Several research firms have recently issued reports on INSM. Zacks Investment Research raised shares of Insmed from a “hold” rating to a “buy” rating and set a $22.00 price target for the company in a research note on Wednesday, April 26th. Stifel Nicolaus increased their price objective on shares of Insmed from $23.00 to $27.00 and gave the stock a “buy” rating in a research report on Monday, May 1st. BidaskClub upgraded shares of Insmed from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd. Robert W. Baird began coverage on shares of Insmed in a research report on Monday, July 10th. They set an “outperform” rating and a $23.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating on shares of Insmed in a research report on Wednesday, August 2nd.
In related news, General Counsel Christine A. Pellizzari purchased 10,000 shares of Insmed stock in a transaction on Wednesday, May 31st. The stock was acquired at an average cost of $15.14 per share, for a total transaction of $151,400.00. Following the completion of the acquisition, the general counsel now owns 27,300 shares of the company’s stock, valued at approximately $413,322. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 4.03% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Insmed, Inc. (INSM) Receives Consensus Recommendation of “Hold” from Brokerages” was published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.com-unik.info/2017/08/19/insmed-incorporated-insm-receives-consensus-rating-of-buy-from-brokerages-updated-updated.html.
Shares of Insmed (NASDAQ INSM) opened at 11.75 on Tuesday. The firm’s market cap is $732.93 million. The firm’s 50-day moving average is $16.40 and its 200-day moving average is $16.39. Insmed has a 12-month low of $10.21 and a 12-month high of $19.35.
Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by $0.09. Analysts predict that Insmed will post ($2.70) earnings per share for the current fiscal year.
Insmed Company Profile
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
What are top analysts saying about Insmed Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Insmed Inc. and related companies.